ERBB2 and gastric cancer: They found that lapatinib (a dual EGFR and HER2 TKI)-resistant HER2-posititve gastric cancer cells upregulated phosphorylation of EGFR/HER2, and MET appeared to be closely related to the activation of PI3K/AKT and ERK1/2.